RxDoctor Payments DataLook up a doctor →

Marc Grobman, DO

Family Medicine · Wilmington, DENPI 1063484442

Payments from drug & device makers

$13,105in general payments, 2019–2025

Across 767 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$1K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Amgen$1K
  • Lilly USA, LLC$765
  • plus $6K from 48 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)108$1,604
GSK85$1,492
Novo Nordisk102$1,299
AstraZeneca54$1,134
Amgen52$1,001
Lilly USA, LLC41$765
Pfizer47$668
Johnson & Johnson10$433
Sanofi-aventis U.S. LLC17$415
Bausch Health US, LLC27$399
Esperion Therapeutics, Inc.23$374
Merck24$369
Boehringer Ingelheim22$345
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC15$322
Astellas Pharma US Inc19$302
Vanda Pharmaceuticals Inc.7$243
Abbott10$187
Bayer9$181
Takeda Pharmaceuticals U.S.A., Inc.11$134
Otsuka America Pharmaceutical, Inc.7$130
Teva Pharmaceuticals USA, Inc.7$123
Kowa Pharmaceuticals America, Inc.8$110
Novartis6$96
Exact Sciences4$84
Corium, LLC3$83
Axsome Therapeutics, Inc.3$70
Eisai Inc.3$58
Idorsia Pharmaceuticals US Inc3$58
Protega Pharmaceutials Inc3$55
Biohaven Pharmaceuticals, Inc.4$53
Xeris Pharmaceuticals, Inc.3$51
Arbor Pharmaceuticals, Inc.3$44
Amarin Pharma, Inc.3$43
Ironwood Pharmaceuticals, Inc2$35
Biohaven Pharmaceutical Holding Company Ltd.2$29
Sunovion Pharmaceuticals Inc.2$24
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$21
Redhill Biopharma Inc.1$20
Sanofi Pasteur Inc.1$20
Ardelyx, Inc.1$19
Lundbeck LLC1$17
Collegium Pharmaceutical, Inc.1$17
Verona Pharma, Inc.1$17
Resmed Corp1$17
Acerus Pharmaceuticals Corporation1$17
Otsuka Pharmaceutical Development & Commercialization, Inc.1$16
Azurity Pharmaceuticals, Inc.1$16
Alnylam Pharmaceuticals Inc.1$16
Endo Pharmaceuticals Inc.1$16
Shire North American Group Inc1$15
Avanir Pharmaceuticals, Inc.1$13
Avion Pharmaceuticals1$13
E.r. Squibb & Sons, L.L.C.1$13
Circassia Inc.1$12

How this compares

$13,105 in reported general payments places this provider in the 95th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$210,384
Medicare patients
314
Services billed
2,407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →